AGN 242428

Drug Profile

AGN 242428

Alternative Names: AGN-242428; VTP43742

Latest Information Update: 06 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vitae Pharmaceuticals
  • Developer Allergan
  • Class Antipsoriatics; Small molecules
  • Mechanism of Action Immunosuppressants; Nuclear receptor subfamily 1 group F member 3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Autoimmune disorders; Multiple sclerosis; Plaque psoriasis; Psoriasis

Most Recent Events

  • 17 May 2018 Vitae Pharmaceuticals terminates a phase II trial due to safety reasons in Plaque psoriasis in USA (PO) (NCT03339999)
  • 30 Apr 2018 Discontinued - Phase-I for Autoimmune disorders in USA (PO)
  • 30 Apr 2018 Discontinued - Phase-II for Plaque psoriasis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top